Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor

Kura Oncology NASDAQ: KURA and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies said showed beta-cell expansion, improved glucose control and sustained effects after treatment ended.

MarketBeat • Oct 14, 2026

Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript

Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript

Seeking Alpha • Oct 13, 2026

Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes

– EASD findings support clinical evaluation of a next-generation oral menin inhibitor designed to restore insulin-producing capacity – – IND-enabling development underway to support Phase 1 clinical proof-of-concept study to assess safety and endogenous insulin production – – Investor webcast today, October 13, 2026, at 4:30 p.m. ET / 1:30 p.m.

GlobeNewsWire • Oct 13, 2026

Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in Diabetes

– Webcast scheduled for October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT – – Webcast scheduled for October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT –

GlobeNewsWire • Oct 7, 2026

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on October 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 128,250 shares of common stock to nine (9) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire • Oct 2, 2026

Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes

– KO-7246 regenerated functional β - cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models –

GlobeNewsWire • Sep 29, 2026

Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 16, 2026

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

– $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful biotech entrepreneurs – – Preclinical studies with KO-7246 demonstrate selective expansion of pancreatic β cells, increased endogenous insulin production, and improved glycemic control across multiple models of Type 1 and Type 2 diabetes – – Preclinical data supporting KO-7246 selected for oral presentation at European Association for the Study of Diabetes (EASD) Annual Meeting on September 29, 2026 – – Separately financed subsidiary provides dedicated capital and leadership to advance KO-7246 through initial clinical proof of concept while Kura retains a substantial ownership stake in Caspian, representing approximately half of the company on a fully diluted basis, and remains focused on oncology – SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced the launch of Caspian Therapeutics, Inc. (“Caspian”), a separately financed company established to advance small-molecule menin inhibitors for diabetes and cardiometabolic diseases.

GlobeNewsWire • Sep 9, 2026

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

– Seasoned public company CFO with deep biopharmaceutical finance experience across commercial operations, R&D portfolio management, investor relations, and capital allocation –  SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced the appointment of Jennifer Fulk as Chief Financial Officer, effective September 8, 2026.

GlobeNewsWire • Sep 8, 2026

Kura Oncology to Participate in Three Investor Conferences in September

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences: Wells Fargo Healthcare ConferenceSeptember 8, 20263:45 p.m.

GlobeNewsWire • Sep 1, 2026